| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 34.1 | 11.7 |
| Profit before tax | -9.3 | -58.9 |
| Net income | -10.5 | -59.1 |
| EPS (diluted, $ a share) | $-0.15 | $-0.85 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +190.2% |
|---|---|
| Operating margin | -39.6% |
10-Q filed with the SEC, NASDAQ: BCYC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bicycle Therapeutics PLC: key numbers
- Share price
- $3.20Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bicycle Therapeutics PLC
All →Bicycle Therapeutics Financial Results
Bicycle Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $469.9 million and a runway extending into 2030. The company also announced that the FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer and plans to initiate its first company-sponsored radioligand clinical trial in 2H 2027.
“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands.”
Kevin Lee, Ph.D., Bicycle CEO
“We remain focused on disciplined execution across our prioritized programs and believe our growing clinical data continue to demonstrate the potential of Bicycle® molecules to deliver highly targeted therapies with differentiated benefit/risk profiles.”
Kevin Lee, Ph.D., Bicycle CEO
Bicycle Therapeutics Director Robert Charles Swanton Sells $11.9K of Stock
Robert Charles Swanton, Director, sold 3,431 shares of Bicycle Therapeutics PLC at $3.47 a share, worth $11.9K in total on Oct 2, 2026. Shares held after the trade: 15,782 (-17.9%).
- Value
- $11.9K
- Shares
- 3,431
- Price
- $3.47
- Role
- Director
- Holding change
- -17.9%
- Trade date
- Oct 2, 2026
Bicycle Therapeutics CEO Kevin Lee Sells $21.4K of Stock
Kevin Lee, CEO, sold 6,167 shares of Bicycle Therapeutics PLC at $3.47 a share, worth $21.4K in total on Oct 2, 2026. Shares held after the trade: 597,504 (-1.0%).
- Value
- $21.4K
- Shares
- 6,167
- Price
- $3.47
- Role
- CEO
- Holding change
- -1.0%
- Trade date
- Oct 2, 2026